Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, February 12, 2016
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet
Monday, February 1, 2016
Eisai Acquires Exclusive License from Huya Bioscience International to Develop and Market HDAC Inhibitor HBI-8000 in Japan and Other Asian Countries
Tuesday, January 12, 2016
Eisai Submits New Application in Europe for In-House Developed Anticancer Agent Lenvatinib Seeking Approval for Indication Covering Renal Cell Carcinoma
Friday, December 11, 2015
MHLW Approves Partial Label Change for Egg-White Lysozyme Preparation Neuzym
Tuesday, December 1, 2015
Eisai and Toyama Chemical Clear All-Case Surveillance Condition for Approval of Antirheumatic Agent Iguratimod
U.S. FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq
Tuesday, November 17, 2015
Successful Ruling in Patent Infringement Litigation for Antiemetic Agent Aloxi in the United States
Thursday, November 5, 2015
Eisai to Commence Two Joint Research Programs toward Development of New Antimalarial Medicines
Monday, November 2, 2015
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan Oral Presentation Given at 49th Congress of The Japan Epilepsy Society
Monday, October 19, 2015
Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in the Lancet Oncology

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: